Assessment of the Safety and Efficacy of Balstilimab in Combination With Botensilimab for the Treatment of Non-Small Cell Lung Cancer (IMMONC0008)
Clinical trial NCT06322108 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT06322108
- Sponsor
- Immune Oncology Research Institute
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2024-06-13
- Primary completion
- 2030-04-01
- Enrollment
- 45
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.